Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salivary pepsin testing for diagnosis of infant gastroesophageal reflux disease
NL-OMON28151Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of omeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Salivary pepsin A concentration in healthy controls, Baseline salivary pepsin A versus healthy controls and 1 more. Planned start May 2014; status: not yet recruiting.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON28151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28151.